Merck & Company with ticker code (MRK) now have 25 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The range between the high target price and low target price is between 115 and 70 and has a mean target at 92.58. Now with the previous closing price of 77.22 this would imply there is a potential upside of 19.9%. There is a 50 day moving average of 77.88 while the 200 day moving average is 77.54. The company has a market capitalisation of $192,881m. You can visit the company’s website by visiting: https://www.merck.com
The potential market cap would be $231,247m based on the market concensus.
Merck & Co. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women’s health, as well as vaccine products. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Synthekine Inc.; and Ridgeback Biotherapeutics. It also has collaboration agreements with Hummingbird Bioscience Pte. Ltd; Gilead Sciences to co-develop and co-commercialize investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; Linnaeus Therapeutics to evaluate LNS8801; Biomed X Gmbh for building on ongoing research projects in the fields of oncology and autoimmunity; NGM Biopharmaceuticals to focus on the development of medicines in retinal and CVM diseases, as well as to develop and commercialize tests that identify genetic mutations; and IO Biotech ApS to evaluate IO102-IO103. It also has a partnership with Biocorp Production for the development and supply of Mallya device; and a licensing agreement with The Medicines Patent Pool to facilitate access for molnupiravir, an investigational oral COVID-19 antiviral medicine. Merck & Co. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
